Back to Search Start Over

Tissue ACE phenotyping in prostate cancer.

Authors :
Danilov SM
Kadrev AV
Kurilova OV
Tikhomirova VE
Kryukova OV
Mamedov VN
Kamalov DM
Danilova NV
Okhobotov DA
Gayfullin NM
Evdokimov VV
Alekseev BJ
Kost OA
Samokhodskaya LM
Kamalov AA
Source :
Oncotarget [Oncotarget] 2019 Oct 29; Vol. 10 (59), pp. 6349-6361. Date of Electronic Publication: 2019 Oct 29 (Print Publication: 2019).
Publication Year :
2019

Abstract

Epithelial cells of prostate express significant level of ACE and, as a result, seminal fluid has 50-fold more ACE than plasma. The substitution of highly specialized prostate epithelial cells by tumor cells results in dramatic decrease in ACE production in prostate tissues. We performed detailed characterization of ACE status in prostate tissues from patients with benign prostate hyperplasia (BPH) and prostate cancer (PC) using new approach- ACE phenotyping, that includes evaluation of: 1) ACE activity with two substrates (HHL and ZPHL); 2) the ratio of the rates of their hydrolysis (ZPHL/HHL ratio); 3) the ratio of immunoreactive ACE protein to ACE activity; 4) the pattern of mAbs binding to different epitopes on ACE - ACE conformational fingerprint - to reveal conformational changes in prostate ACE due to prostate pathology. ACE activity dramatically decreased and the ratio of immunoreactive ACE protein to ACE activity increased in PC tissues. The catalytic parameter, ZPHL/HHL ratio, increased in prostate tissues from all patients with PC, but was did not change for most |BPH patients. Nevertheless, prostate tissues of several patients diagnosed with BPH based on histology, also demonstrated decreased ACE activity and increased immunoreactive ACE protein/ACE activity and ZPHL/HHL ratios, that could be considered as more early indicators of prostate cancer development than routine histology. Thus, ACE phenotyping of prostate biopsies has a potential to be an effective approach for early diagnostics of prostate cancer or at least for differential diagnostics of BPH and PC.<br />Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest<br /> (Copyright: © 2019 Danilov et al.)

Details

Language :
English
ISSN :
1949-2553
Volume :
10
Issue :
59
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
31695843
Full Text :
https://doi.org/10.18632/oncotarget.27276